In NSCLC patients with activating EGFR mutations, EGFR tyrosine kinase inhibitors (EGFR-TKI) have a remarkable impact and prolonged survival compared with standard treatments [43–45]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.